Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 5
1977 1
1978 2
1979 1
1980 4
1981 2
1982 1
1983 2
1984 3
1985 3
1986 5
1987 3
1988 5
1989 5
1990 8
1991 2
1992 9
1993 8
1994 22
1995 12
1996 9
1997 12
1998 17
1999 13
2000 21
2001 15
2002 13
2003 15
2004 16
2005 14
2006 18
2007 30
2008 23
2009 26
2010 30
2011 39
2012 58
2013 66
2014 49
2015 55
2016 44
2017 56
2018 61
2019 44
2020 61
2021 50
2022 32
2023 39
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

926 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Lung Squamous Cell Carcinoma"
Page 1
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G; Cancer Genome Atlas Research Network; Artyomov MN, Schreiber R, Govindan R, Meyerson M. Campbell JD, et al. Nat Genet. 2016 Jun;48(6):607-16. doi: 10.1038/ng.3564. Epub 2016 May 9. Nat Genet. 2016. PMID: 27158780 Free PMC article.
To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to identify new drivers of lung carcinogenesis, we examined the exome sequences and copy number profiles of 660 lung ADC and 484 lung SqCC tumo …
To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to identify new drivers …
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Redman MW, et al. Lancet Oncol. 2020 Dec;21(12):1589-1601. doi: 10.1016/S1470-2045(20)30475-7. Epub 2020 Oct 27. Lancet Oncol. 2020. PMID: 33125909 Free PMC article. Clinical Trial.
BACKGROUND: The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to address an unmet need for better therapies for squamous non-small-cell lung cancer. ...Eligible patients were aged 18 years …
BACKGROUND: The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to addr …
SAMD9 Promotes Postoperative Recurrence of Esophageal Squamous Cell Carcinoma by Stimulating MYH9-Mediated GSK3beta/beta-Catenin Signaling.
Li Q, Luo H, Dai FQ, Wang RT, Fan XQ, Luo YY, Deng MS, Wang Y, Long T, Guo W, Xu B, Xu CX, Jin H. Li Q, et al. Adv Sci (Weinh). 2023 Apr;10(11):e2203573. doi: 10.1002/advs.202203573. Epub 2023 Feb 9. Adv Sci (Weinh). 2023. PMID: 36757050 Free PMC article.
Recurrence is a challenge to survival after the initial treatment of esophageal squamous cell carcinoma (ESCC). But, its mechanism remains elusive and there are currently no biomarkers to predict postoperative recurrence. Here, the possib …
Recurrence is a challenge to survival after the initial treatment of esophageal squamous cell carcinoma (ESCC). …
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. Waqar SN, et al. Clin Lung Cancer. 2021 May;22(3):170-177. doi: 10.1016/j.cllc.2020.09.013. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33221175 Free PMC article. Clinical Trial.
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET-positive squamous cell carcinoma (SCC). ...CONCLUSION: Telisotuzumab vedotin failed to meet …
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c- …
Pulmonary blastomas.
Koss MN, Hochholzer L, O'Leary T. Koss MN, et al. Cancer. 1991 May 1;67(9):2368-81. doi: 10.1002/1097-0142(19910501)67:9<2368::aid-cncr2820670926>3.0.co;2-g. Cancer. 1991. PMID: 1849449
Pulmonary blastoma is a rare lung tumor composed of immature mesenchyme and/or epithelium that morphologically mimics embryonal pulmonary structure. The prognosis of these tumors is poor, and the clinical course is not readily predicted from histologic appearance. I …
Pulmonary blastoma is a rare lung tumor composed of immature mesenchyme and/or epithelium that morphologically mimics embryonal pulmo …
Segmentectomy for clinically early-stage primary squamous cell carcinoma of the lung.
Kagimoto A, Tsutani Y, Shimada Y, Mimae T, Miyata Y, Ito H, Nakayama H, Ikeda N, Okada M. Kagimoto A, et al. Thorac Cancer. 2022 Dec;13(24):3477-3485. doi: 10.1111/1759-7714.14707. Epub 2022 Nov 8. Thorac Cancer. 2022. PMID: 36346136 Free PMC article.
BACKGROUND: Squamous cell carcinoma of the lung-the second most common subtype of lung cancer-has a poorer prognosis than lung adenocarcinoma. ...CONCLUSIONS: Segmentectomy may be feasible for treating clinically early-stage lung …
BACKGROUND: Squamous cell carcinoma of the lung-the second most common subtype of lung cancer-has a poore …
Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma.
Kinoshita F, Oku Y, Takamori S, Fujishita T, Toyozawa R, Ito K, Shoji F, Okamoto T. Kinoshita F, et al. Invest New Drugs. 2023 Feb;41(1):168-172. doi: 10.1007/s10637-022-01312-9. Epub 2022 Nov 4. Invest New Drugs. 2023. PMID: 36331673
BACKGROUND: The efficacy and safety of the anti-EGFR antibody necitumumab combined with gemcitabine and cisplatin (N + GC) in the first-line treatment of advanced lung squamous cell carcinoma (LSCC) have been proven. However, the efficacy and safety of …
BACKGROUND: The efficacy and safety of the anti-EGFR antibody necitumumab combined with gemcitabine and cisplatin (N + GC) in the first-line …
Clinicopathologic features of peripheral squamous cell carcinoma of the lung.
Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Sakurai H, et al. Ann Thorac Surg. 2004 Jul;78(1):222-7. doi: 10.1016/j.athoracsur.2004.01.029. Ann Thorac Surg. 2004. PMID: 15223433 Review.
BACKGROUND: The clinicopathologic features are still unknown in peripheral squamous cell carcinoma of the lung, unlike centrally located carcinomas. ...The 5-year overall and disease-specific survival rates were 73.4% and 85.9%, respectively. The cause …
BACKGROUND: The clinicopathologic features are still unknown in peripheral squamous cell carcinoma of the lung, …
Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.
Shen C, Shyu DL, Xu M, Yang L, Webb A, Duan W, Williams TM. Shen C, et al. Mol Cancer Res. 2022 Mar 1;20(3):425-433. doi: 10.1158/1541-7786.MCR-21-0272. Mol Cancer Res. 2022. PMID: 34810212 Free PMC article.
Lung squamous cell carcinoma (LUSC) accounts for one of three of non-small cell lung carcinoma (NSCLC) and 30% of LUSC patients present with locally advanced, unresectable/medically inoperable disease, who are commonly treated with …
Lung squamous cell carcinoma (LUSC) accounts for one of three of non-small cell lung carcinoma …
Rare cavitary lymphoepithelioma-like carcinoma of lung: clinical experience and literature review.
Chen G, Yu Q, Ran H, Li X, Zhang T. Chen G, et al. BMC Pulm Med. 2023 Jul 5;23(1):246. doi: 10.1186/s12890-023-02529-x. BMC Pulm Med. 2023. PMID: 37407960 Free PMC article. Review.
BACKGROUND: Lymphoepithelioma-like carcinoma of the lung is a rare primary malignancy of the lung, accounting for only 0.9% of primary malignancies of the lung. ...Postoperative pathology confirmed primary pulmonary lymphoepithelioma-like carcinoma …
BACKGROUND: Lymphoepithelioma-like carcinoma of the lung is a rare primary malignancy of the lung, accounting for only …
926 results